SCHEMBL29334162

SCHEMBL29334162

CC(C)(C)OC(=O)N1CCOC[C@H]1c1cc(Cl)cc(-c2ccnc(Cl)n2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MALT1 Q9UDY8 1/20 0.40
▸ AAK1 Q2M2I8 3/20 0.37
▸ PIK3R1 P27986 6/20 0.36
▸ PIK3CA P42336 6/20 0.36
▸ CCNC P24863 1/20 0.35
▸ CDK8 P49336 1/20 0.35
▸ KCNK3 O14649 1/20 0.35
▸ KCNK9 Q9NPC2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ USP30 Q70CQ3 2/20 0.34
▸ UCHL1 P09936 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34
▸ HDAC5 Q9UQL6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30855103 1.00 MALT1 (0.40) MALT1AAK1PIK3R1PIK3CACCNC
SCHEMBL29333868 0.85 UCHL1 (0.41) MALT1PIK3R1PIK3CACCNCCDK8
SCHEMBL30855205 0.85 UCHL1 (0.41) MALT1PIK3R1PIK3CACCNCCDK8
SCHEMBL29333870 0.83 NR1H2 (0.42) MALT1CCNCCDK8TSHRUSP30
SCHEMBL29333832 0.83 NR1H2 (0.42) MALT1CCNCCDK8TSHRUSP30
SCHEMBL29333887 0.82 MALT1 (0.39) MALT1PIK3R1PIK3CACCNCCDK8
SCHEMBL29333946 0.82 MALT1 (0.37) MALT1PIK3R1PIK3CACCNCCDK8
SCHEMBL30855146 0.82 MALT1 (0.37) MALT1PIK3R1PIK3CACCNCCDK8
SCHEMBL29333891 0.81 MALT1 (0.37) MALT1PIK3R1PIK3CACCNCCDK8
SCHEMBL31224883 0.79 MALT1 (0.44) MALT1PIK3R1PIK3CACCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226114-A1 INHIBITORS AND USES THEREOF KEAP1, NQO1, NFE2L2 MALT1 4516/4885AAK1 852/4885PIK3R1 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback